Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: A single institution phase II study in 24 patients

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 1, 2006, Pages 60-67

  Fuso, L ^a   Amant, F ^a   Neven, P ^a   Berteloot, P ^a   Vergote, I ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Carboplatin; Chemotherapy; Gemcitabine; Neoplasms; Ovarian; Ovarian cancer; Paclitaxel; Therapy

Indexed keywords

CARBOPLATIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART PALPITATION; HUMAN; ILEUS; MEDICAL ASSESSMENT; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SEPTIC SHOCK; SHOCK; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 33645340337     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00315.x     Document Type: Article

References (53)

1. Ries LAG Eisner MP Kosary CL et al. eds. SEER cancer statistics review, 1973-1999. Bethesda, MD National Cancer Institute 2002. Available at http://seer.cancer.gov/csr/1973_1999/ovary.pdf.
2. Runnebaum IB Stickeler E Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001 127 73 9.
3. Jemal A Tiwari RC Murray T et al and American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004 54 8 29.
4. Aabo K Adams M Adnitt P et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998 78 1479 87.
5. McGuire W Hoskins W Brady M et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 334 1 6.
6. Piccart MJ Bertelsen K James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000 92 699 708.
7. Piccart MJ Bertelsen K Stuart G et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 2003 13 Suppl. 2 144 8.
8. Muggia FM Braly PS Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000 18 106 15.
9. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002 360 505 15. Erratum in Lancet 2003 361 706.
10. Du Bois A Luck HJ Meier W et al. Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003 95 1320 9.
11. Neijt JP Engelholm SA Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000 18 3084 92.
12. Ozols RF Bundy BN Greer BE et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003 21 3194 200.
13. van Moorsel CJ Peters GJ Pinedo HM. Gemcitabine: future prospects of single-agent and combination studies. Oncologist 1997 2 127 34.
14. Vogelzang NJ. Future directions for gemcitabine in the treatment of genitourinary cancer. Semin Oncol 2002 29 1 Suppl. 3 40 5.
15. Mackey JR Mani RS Selner M et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998 58 4349 57.
16. Heinemann V Hertel LW Grindey GB Plunkett W. Comparison of the cellular pharmaco-kinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-darabinofuranosylcytosine. Cancer Res 1988 48 4024 31.
17. Ruiz van Haperen VW Veerman G Vermorken JB Peters GJ. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 1993 46 762 6.
18. Heinemann V Xu YZ Chubb S et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990 38 567 72.
19. Huang C Chubb S Hertel LW Grindey GB Plunkett W. Action of 2′2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991 51 6110 7.
20. Plunkett W Huang P Searcy CE Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996 23 5 Suppl. 10 3 15. Review.
21. Van Moorsel CJ Pinedo HM Veerman G et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999 80 981 90.
22. Bergman AM Ruiz van Haperen VW Veerman G Kuiper CM Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996 2 521 30.
23. Aapro MS Martin C Hatty S. Gemcitabine - a safety review. Anticancer Drugs 1998 9 191 201.
24. Ricci S Antonuzzo A Galli L et al. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced non-small cell lung carcinoma. Cancer 2000 89 1714 9.
25. Ozols RF. The current role of gemcitabine in ovarian cancer. Semin Oncol 2001 28 2 Suppl. 7 18 24.
26. Lund B Hansen OP Theilade K Hansen M Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994 86 1530 3.
27. Shapiro JD Millward MJ Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996 63 89 93.
28. Friedlander M Millward MJ Bell D et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998 9 1343 5.
29. Lund B Neijt JP. Gemcitabine in cisplatin-resistant ovarian cancer. Semin Oncol 1996 23 5 Suppl. 10 72 6.
30. Morhan-Ihirig C Lembersky B Christopherson W Tarassoff P. A phase II evaluation of difluorodeoxycytidine (dfdc) in advanced stage refractory ovarian cancer (meeting abstract) [abstract]. Proc Am Soc Clin Oncol 1991 10 A646.
31. Markman M Kennedy A Webster K et al. Phase 2 trial of single-agent gemcitabine (GEM) in platinum (PLAT)/paclitaxel (PAC) refractory ovarian cancer (ROC) [abstract]. Proc Am Soc Clin Oncol 2001 20 204a. Abstract 813.
32. D'Agostino G Amant F Berteloot P Scambia G Vergote I. Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003 88 266 9.
33. Peters GJ Bergman AM Ruiz van Haperen VW Veerman G Kuiper CM Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995 22 4 Suppl. 11 72 9.
34. Kunkel LM Evans SS Dottino PR et al. Cisplatin and gemcitabine in relapsed ovarian carcinoma. Proc Am Soc Clin Oncol 1998 17 A1379.
35. Velasco X Matilde M Pérez et al. Gemcitabine and cisplatin as treatment for patients with platinum resistant ovarian cancer and as consolidation treatment for patients with residual disease after first-line chemotherapy [abstract]. Proc Am Soc Clin Oncol 2001 20 182b. Abstract 2477A.
36. Du Bois A Luck HJ Pfisterer J et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol 2001 12 1115 20.
37. Poole CJ Perren T Hogberg I et al. Phase I to investigate the optimal dose and schedule of gemcitabine and paclitaxel in combination in patients with previously treated epithelial ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1998 17 357a. Abstract 1380.
38. Roman L Garcia AA Facio G et al. Phase II study of weekly paclitaxel and gemcitabine in platinum resistant ovarian cancer [abstract]. Proc Am Soc Clin Oncol 2001 20 220a. Abstract 877.
39. Hansen SW Anderson H Boman K et al. Gemcitabine, carboplatin, paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV [abstract]. Proc Am Soc Clin Oncol 1999 18 357. Abstract 1379.
40. Geertsen P Hansen M Stroyer I Hansen SW. Combination chemotherapy with platinum, paclitaxel and gemcitabine in patients with relapsed ovarian carcinoma [abstract]. Proc Am Soc Clin Oncol 1999 18 357. Abstract 1395.
41. Look KY Bookman MA Schol J et al. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2004 92 93 100.
42. Barlow C Nystrom M Oesterling C Fennell D Ismay J Gallagher C. Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer. Br J Cancer 2004 90 1318 22.
43. Hansen SW. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol 2002 29 1 Suppl. 1 17 9. Review.
44. Therasse P Arbuck SG Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 205 16.
45. Vergote I Rustin GJ Eisenhauer EA et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000 92 1534 5.
46. Rustin GJ Quinn M Thigpen T et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004 96 487 8.
47. Eisenhauer EA ten Bokkel Huinink WW Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994 12 2654 66.
48. Kristensen GB Vergote I Stuart G et al. First-line treatment of ovarian cancer FIGO stages Iib-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 2003 13 Suppl. 2 172 7.
49. Guppy AE Nelstrop AE Foster T Agarwal R Seckl MJ Rustin GJ. A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer 2004 90 810 4.
50. Kelly K Mikhaeel-Kamel N Pan Z Murphy J Prindiville S Bunn PA Jr.. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 2000 6 3474 9.
51. Hussein A Birch R Waller J et al. Preliminary results of a randomized study comparing paclitaxel and carboplatin (PC) with or without gemcitabine (G) in newly diagnosed non small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2000 19 504A. Abstract 1973.
52. Harries M Moss C Perren T et al. A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer 2004 91 627 32.
53. Vasey PA. Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2002 21 202a. Abstract 804.